Can a 36-year-old woman who is breastfeeding safely take rosuvastatin?

No, a 36-year-old woman should not take rosuvastatin while breastfeeding.

Breastfeeding is not recommended during treatment with rosuvastatin according to the FDA drug label 1. The medication should be discontinued if breastfeeding is desired, or breastfeeding should be avoided if the medication is necessary.

Rationale Based on FDA Guidance

The FDA explicitly states that "breastfeeding is not recommended during treatment with rosuvastatin" 1. This recommendation is based on:

• Limited data showing rosuvastatin is present in human milk 1
• Mechanism of action concerns: Statins decrease cholesterol synthesis and potentially other biologically active substances derived from cholesterol, which may harm the breastfed infant 1
• Potential for serious adverse reactions in the breastfed infant based on the drug's mechanism 1

Supporting Evidence from Clinical Practice

While the FDA label provides the definitive guidance, recent real-world data offers additional context:

• A 2025 case report documented safe use in one 13-month-old infant whose mother used rosuvastatin, with normal lipid profiles and neurodevelopmental outcomes at 18 months 2
• However, this represents only a single case and cannot override the FDA's precautionary stance

Clinical Decision Algorithm

If the patient requires lipid-lowering therapy:

1. Discontinue rosuvastatin and delay treatment until after breastfeeding cessation
2. Consider non-pharmacologic interventions (diet, exercise) during the breastfeeding period
3. If cardiovascular risk is extremely high and treatment cannot be delayed, advise the patient to discontinue breastfeeding before initiating rosuvastatin 1

Important context: Women with conditions like familial hypercholesterolemia may lose significant treatment time (median 2.3 years) during pregnancy and breastfeeding periods 3, but the FDA guidance prioritizes infant safety over maternal treatment continuity in this situation.

Key Caveats

• The AAP guideline notes that most maternal medications are compatible with breastfeeding 4, but rosuvastatin is specifically contraindicated by its FDA label
• Alternative statins (like atorvastatin) show minimal milk transfer 5, but rosuvastatin's FDA label remains more restrictive
• The theoretical risk to infant cholesterol synthesis and development takes precedence over the limited reassuring case data